Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Additions to Restructuring Provisions During the Year by Year
Additions to Restructuring Provisions During the Year ($M)
Novartis Additions to Restructuring Provisions During the Year: $364M in FY2025, up 0.6% from a year earlier.
Latest, FY2025
364
Period ended Dec 31, 2025
Change on a year earlier
+0.6%
362 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Additions to Restructuring Provisions During the Year ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 364 | +0.6% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 362 | -45.0% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 658 | -53.0% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2022 | Dec 31, 2022 | 1,400 | +326.8% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2021 | Dec 31, 2021 | 328 | -7.3% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2020 | Dec 31, 2020 | 354 | -28.0% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2019 | Dec 31, 2019 | 492 | -7.9% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2018 | Dec 31, 2018 | 534 | +175.3% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2017 | Dec 31, 2017 | 194 | -43.4% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2016 | Dec 31, 2016 | 343 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Cite this data
StockData. (2026). Novartis Additions to Restructuring Provisions During the Year ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/prov-restructuring-additions
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.